Ananda Pharma PLC - Confirmation of receipt of £168k R&D tax refund
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF

10
ANANDA PHARMA PLC
("Ananda" or the "Company")
Confirmation of receipt of
Ananda Pharma plc (AQSE: ANA, OTCQB: ANANF), a
The Company expects to receive a further refund in Q3 2026, in relation to expenditure on the Phase 1 pharmacokinetic (PK) study completed in
Ananda's Chief Executive Officer,
The Phase I, Open-Label, Multiple Dose Study to Assess the Pharmacokinetics, Safety, Tolerability and Food Effect of MRX1 in Healthy Adults is sponsored by the Company's wholly owned Australian subsidiary, Tiamat Australia Pty Ltd, and run in partnership with Australian CRO Southern Star Research. The objectives of the study have been to assess the safety and tolerability of MRX1 and to assess the pharmacokinetic profile of MRX1 in both men and women.
The study commenced dosing on
Ananda expects to receive final safety and tolerability data from the trial in Q4 2025, with the final study report including pharmacokinetic results to be finalised in Q1 2026. The data generated from this study will become part of the clinical data package supporting MRX1 in future regulatory filings with regulators such as the FDA, EMA and MHRA. It will also help to inform future clinical trial protocols and the development of suitable dosing regimens.
About Ananda Pharma
Ananda Pharma (AQSE: ANA) is a
For more information, please visit our website:
To stay up to date with Ananda's news please follow our social media channels:
· Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93
· Instagram: https://www.instagram.com/anandapharmaplc/
· LinkedIn: https://www.linkedin.com/company/anandapharma
· X: https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor
-Ends-
For the purposes of
|
ANANDA PHARMA PLC |
+44 (0)7463 686 497 |
|
|
|
|
Chief Executive Officer |
|
|
|
|
|
|
|
|
Finance Director |
|
|
|
|
|
|
|
|
SP ANGEL CORPORATE FINANCE LLP |
|
|
|
|
|
Corporate Finance |
+44 (0)20 3470 0470 |
|
|
|
|
|
|
|
|
|
|
Corporate Broking |
+44 (0)20 3470 0534 |
|
|
|
|
|
|
|
|
|
|
|
|
|
VIRIDIAN CAPITAL ADVISORS (US) |
+1 (646) 330-0704
|
https://investors.anandapharma.co.uk/link/e95vDe
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE